Coronavirus BRIEFING
Supported by Essilor

The Latest COVID-19 Data

The National Average for Gross Revenue at ECP Locations Decreased for the Week of June 17–23, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 27, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations decreased last week, June 17–23, when compared with the previous week, at a rate of -1 index point. That places gross revenue at a level 11 index points above where it was at this point in time (Week 25) when compared with last year (2023), 18 points above the same period in 2022, 22 points above 2021, 21 points above 2020 and 28 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

How to Fix $1.6 Billion Long COVID Program: Experts Weigh In

By Staff
Wednesday, June 26, 2024 8:02 AM When the National Institutes of Health (NIH) launched a $1 billion dollar research effort in 2021 focused on long COVID, hopes were high that it would lead to some answers for the mysterious riddle of the complex condition. Now, more than 3 years later and with total funding of about $1.6 billion, critics contend the federal government has little to show for its efforts.

Cannabis Use Tied to Increased Risk of Severe COVID

By Staff
Tuesday, June 25, 2024 8:02 AM Cannabis use was significantly associated with a greater risk of severe outcomes following a COVID-19 infection, according to a retrospective study that spanned the first 2 years of the pandemic.

COVID Pandemic May Have Disrupted Cervical Cancer Screenings

By Staff
Monday, June 24, 2024 8:02 AM New research found women aged 21-65 years who were due for a Papanicolaou (Pap) test to screen for cervical cancer were about 30% less likely in 2022 to report having received one in the past year than women were in 2019. The likelihood of Pap testing in the past year did not differ between 2019 and 2020, during the early part of the pandemic.

U.S. Government to Fund Up to $500 Million for Studies on Oral, Nasal COVID Vaccines

By Staff
Friday, June 21, 2024 8:02 AM The U.S. Department of Health and Human Services (HHS) said on Thursday it will provide up to $500 million for mid-stage trials evaluating vaccines administered as a nasal spray or pill to protect against symptomatic COVID-19.

Prenatal Maternal Distress During Pandemic Tied to Newborn Brain Development

By Staff
Friday, June 21, 2024 6:09 AM Left amygdalar volumes were smaller in newborns whose mothers had high psychological distress during the COVID-19 pandemic, a small cross-sectional study suggested.

We Won't Solve Long COVID Until We Decide What It Is

By Staff
Thursday, June 20, 2024 8:02 AM Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Dr F. Perry Wilson of the Yale School of Medicine. I want to help people suffering from long COVID as much as anyone. But we have a real problem. In brief, we are being too inclusive. The first thing you learn, when you start studying the epidemiology of diseases, is that you need a good case definition. And our case definition for long COVID sucks.

The National Average for Gross Revenue at ECP Locations Increased for the Week of June 10–16, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 20, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, June 10–16, when compared with the previous week, at a rate of 3 index points. That places gross revenue at a level 11 index points above where it was at this point in time (Week 24) when compared with last year (2023), 18 points above the same period in 2022, 22 points above 2021, 24 points above 2020 and 29 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

Lawmakers Sharply Question Experts About COVID's Origin

By Staff
Wednesday, June 19, 2024 6:09 AM Accusations flew from the dais to the witness table at a Senate hearing on June 18 as senators and witnesses debated the origins of SARS-CoV-2, the virus that causes COVID-19.

Thousands of Kids Prescribed 'Potentially Harmful' Drugs for Acute COVID

By Staff
Tuesday, June 18, 2024 6:09 AM Clinicians prescribed hydroxychloroquine (HCQ) and ivermectin inappropriately to thousands of children with acute COVID-19, according to a retrospective cohort study.

Here's What Is Wrong With the National Academies' Long COVID Definition

By Staff
Monday, June 17, 2024 6:09 AM The National Academies of Sciences, Engineering, and Medicine has just proposed a new case definition for long COVID. The criteria specify that the condition "is present for at least 3 months as a continuous, relapsing and remitting, or progressive disease state" and the condition can be defined by "single or multiple symptoms" that "can range from mild to severe."

Moderna COVID/Flu Combo Vaccine Superior to Separate Shots in Trial

By Staff
Friday, June 14, 2024 8:02 AM Moderna said its combination vaccine to protect against both COVID-19 and influenza generated a stronger immune response in adults aged 50 and over when compared to separate shots against the viruses in a late-stage trial.

Prior COVID Infection May Protect Against Some Common Colds

By Staff
Friday, June 14, 2024 6:09 AM If you've been sick with COVID-19, you may have some protection against certain versions of the common cold.

The National Average for Gross Revenue at ECP Locations Increased for the Week of June 3–9, Jobson’s Latest Practice Performance Tracker Shows

By Staff
Thursday, June 13, 2024 12:24 AM NEW YORK—The national average for gross revenue at ECP locations increased last week, June 3–9, when compared with the previous week, at a rate of 23 index points. That places gross revenue at a level 30 index points above where it was at this point in time (Week 23) when compared with last year (2023), 37 points above the same period in 2022, 42 points above 2021, 25 points above 2020 and 25 points above 2019, according to Jobson’s most recent Practice Performance Tracker.

National Academies Issue New Broad Definition of Long COVID

By Staff
Wednesday, June 12, 2024 8:02 AM A new broadly inclusive definition of long COVID from the National Academies of Sciences, Engineering, and Medicine (NASEM) has been developed with the aim of improving consistency, documentation, and treatment for both adults and children.